# Small Cell Carcinoma of the Ovary, Pulmonary Type, With a Germline BRCA2 Mutation: A Report of a Rare Case

## TL;DR

A rare case of ovarian cancer with a BRCA2 mutation showed limited response to targeted therapy, highlighting the need for better treatment options.

## Contribution

This report highlights the limited efficacy of PARP inhibitors in SCCOPT despite BRCA2 mutations, suggesting a need for alternative therapies.

## Key findings

- A patient with SCCOPT and a germline BRCA2 mutation showed disease progression despite PARP inhibitor therapy.
- The case suggests that PARP inhibitors may not be effective for SCCOPT even in the presence of BRCA2 mutations.
- Further research is needed to develop more effective treatments for SCCOPT.

## Abstract

Small cell carcinoma of the ovary, pulmonary type (SCCOPT), is a rare and aggressive malignancy with a poor prognosis. We report a rare case of this cancer in a patient with a germline BRCA2 (gBRCA2) mutation. A 66-year-old female patient presented with abdominal distention, underwent a laparotomy, and was diagnosed with stage IVB SCCOPT. Histopathological examination revealed no other ovarian tumor components. Adjuvant platinum-based chemotherapy was administered, followed by maintenance therapy with poly(ADP-ribose) polymerase inhibitors (PARPi) because of the gBRCA2 mutation. Despite expectations of a favorable outcome with the targeted maintenance therapy, disease progression was noted five months after starting maintenance therapy, and the patient died 12 months after surgery. The disease course suggests that maintenance therapy may have limited efficacy against this cancer, even in the presence of gBRCA2 mutations. Further research is necessary to investigate the role of PARPi and establish more effective oncological treatment for this cancer.